Canadian Psychiatric Association

Editorial Credits/ Crédits éditorials

Subscription Rates /Prix d'abonnements

Advertising Rates / Tarifs publicitaires (PDF)

Editorial
The Role of Pharmaceutical Companies in Research and Development — Plaudits and Cautions
Quentin Rae-Grant
(PDF)

Guest Editorial
Diagnostic Concepts and the Prevention of Schizophrenia
Ming T Tsuang, Stephen V Faraone
(PDF)

In Review
Understanding Predisposition to Schizophrenia: Toward Intervention and Prevention
Ming T Tsuang, William S Stone, Stephen V Faraone
(PDF)

Preventing Schizophrenia and Psychotic Behaviour: Definitions and Methodological Issues
Stephen V Faraone, Hendricks Brown, Stephen J Glatt, Ming T Tsuang

(PDF)

Original Research
Association of QEEG Findings With Clinical Characteristics of OCD: Evidence of Left Frontotemporal Dysfunction

Ôenel Tot, Aynur Özge, Ülkü Çömelekolu, Kemal Yazici, Nilgün Bal

(PDF)

Ecstasy and Drug Consumption Patterns: A Canadian Rave Population Study
Samantha R Gross, Sean P Barrett, John S Shestowsky, Robert O Pihl

(PDF)

Research Methods in Psychiatry
The 2 “Es” of Research: Efficacy and Effectiveness Trials

David L Streiner,

(PDF)

Brief Communication
Serum Cholesterol Level Comparison: Control Subjects, Anxiety Disorder Patients, and Obsessive–Compulsive Disorder Patients

Helmut Peter, Iver Hand, Fritz Hohagen, Anne Koenig, Olaf Mindermann, Frank Oeder, Markus Wittich

(PDF)

Perceptions of Intimidation in the Psychiatric Educational Environment in Edmonton, Alberta
Phil Tibbo, CJ de Gara, Treena M Blake, Carolyn Steinberg, Brian Stonehocker

(PDF)

Senior Residents in Psychiatry: Views on Training in Developmental Disabilities
Philip Burge, Hélène Ouellette-Kuntz, Bruce McCreary, Elspeth Bradley, Pierre Leichner

(PDF)

Evidence That Latitude is Directly Related to Variation in Suicide Rates
George E Davis, Walter E Lowell

(PDF)

CPA Position Paper
The 1996 CMA Code of Ethics Annotated for Psychiatrists

 


Book Reviews
(PDF)
Substance Abuse Treatment and the Stages of Change: Selecting and Planning Interventions.

Handbook of Personality Disorders: Theory, Research and Treatment

A Clinical Guide to Sleep Disorders in Children and Adolescents

Love Relations: Normality and Pathology

The Mental Health Matrix: A Manual to Improve Services


Letters to the Editor
(PDF)
Massive Weight Gain and Hostility Force Mirtazapine Stoppage

Functional Dyspepsia and Mirtazapine

Re: Using Language in Psychiatry

Dr Fine Replies

Psychotic Mania in Bipolar II Depression Related to Sertraline Discontinuation

Délirium associé à l’azithromycine

Behavioural Therapy for the Treatment of Alcohol Abuse and Dependence

In Review

Preventing Schizophrenia and Psychotic Behaviour: Definitions and Methodological Issues

Stephen V Faraone, PhD1, C Hendricks Brown, PhD2 , Stephen J Glatt, PhD3,
Ming T Tsuang, MD, PhD4

 

Although schizophrenia onset usually occurs in late adolescence or early adulthood, much research shows that its seeds are planted early in life and that eventual onset occurs at the end of a neurodevelopmental process leading to aberrant brain functioning. This idea, along with the fact that current therapies are far from fully effective, suggests that preventive treatments may be needed to achieve an ideal outcome for schizophrenia patients and those predisposed to the disorder. In this article, we review the methodological challenges that must be overcome before effective preventive interventions can be created. Prevention studies will need to define the target population. This requires the identification of risk factors that will be useful in selecting at-risk people for preventive treatment. We review currently identified risk factors for schizophrenia: genes, psychosocial factors, pregnancy and delivery complications, and viruses. We also review 3 different types of prevention programs: universal, indicated, and selective. For schizophrenia, we distinguish prevention programs that target prodromal cases and those that target the disorder’s premorbid precursors. Although those targeting prodromal cases provide a useful framework for early treatment of the disorder, studies of premorbid individuals are needed to design a truly preventive treatment.

(Can J Psychiatry 2002;47:527–537)

Click here for Research Funding and Support and Author Affiliations

Highlights

  • Research methods need to be developed and refined to prepare for future prevention of schizophrenia before its onset.

  • This review identifies the characteristics of predisposition before schizophrenia onset associated with both genetic and environmental factors (for example, premorbid states such as schizotaxia).

  • To accurately characterize schizotaxia, the reliability and validity of its identified characteristic traits should be tested.

Key Words: schizophrenia, prevention, methodology, prodrome, premorbid, schizotaxia

Résumé : Prévention de la schizophrénie et du comportement psychotique : définitions et questions méthodologiques

Although schizophrenia onset usually occurs in late adolescence or early adulthood, much research shows that its seeds are planted early in life and that the disorder’s eventual onset occurs at the end of a neurodevelopmental process leading to aberrant brain functioning. This, along with the fact that current therapies are far from fully effective, suggests that preventive treatments may be needed to achieve an ideal outcome for schizophrenia patients and those predisposed to the disorder. Among the many challenges to the prevention of schizophrenia is the problem of methodology. Prevention protocols have been implemented for other psychiatric disorders, but can these be applied to schizophrenia? Alternatively, do the unique features of this disorder require novel approaches?

Compared with many other targets of prevention programs, such as drug abuse (1), depression (2,3), child abuse (4), aggression, conduct disorder, and delinquency (5–8), schizophrenia has a low incidence (about 1%). Any study designed to test a prevention strategy must acknowledge this low incidence, as well as the predictability of risk factors and the efficacy of interventions across different subgroups. Without such attention, a prevention trial will likely have minimal power to detect preventive impact. We will show how 3 epidemiologic terms indicating the predictability of a risk factor, the frequency of that risk factor in the population, and the effectiveness of a preventive intervention targeting that risk factor all work together to determine the effect of an intervention strategy on preventing a target outcome.

Understanding Risk and Protective Factors

Defining the Target Population

Modern prevention science is based on the concept of targeting or altering the known risk factors or enhancing the known protective factors that necessarily precede a disorder’s onset (9,10). A risk factor is an element that, when present, is associated with a higher probability of subsequent disorder than that experienced by the population without such a factor. A protective factor is one that lowers risk. For example, estrogen is believed to be a protective factor for schizophrenia, since female sex predicts a delayed onset and reduced prevalence of the disorder (11). By discovering gene variants that predispose to disorders, molecular genetic studies may lead to more precisely defined target populations. For example, the epsilon 4 variant of the apolipoprotein E gene has been shown to increase the risk for late-onset Alzheimer’s disease, the epsilon 2 variant protects against the disease, and other variants have no effect (12).

Although risk and protective factors must precede the outcome of interest, they may be either distant or proximal to onset. Genes and pregnancy and delivery complications are distal risk factors for schizophrenia (13), while drug use is a proximal risk factor for psychosis. Risk and protective factors can be further classified as modifiable or nonmodifiable. Carrying a susceptibility gene for schizophrenia is an example of a nonmodifiable risk factor (there is no gene therapy for schizophrenia). Pregnancy and delivery complications provide a good example of modifiable risk factors because these could be modified by good pre-, peri-, and postnatal care.

We can further classify risk and protective factors with regard to whether they impact individuals or groups. Risk factors occurring at the individual level, such as pregnancy and delivery complications, affect a single individual at a time, not an entire community. Other examples of individual risk factors include child abuse, head injury, and the neurotoxic effects of drug abuse. Risk factors that occur at the group level affect many individuals at once. For example, the school shooting in Columbine, Colorado, traumatized the entire school. Lack of resources in low-income areas leads to poor education, which can impact an entire school district.

Twin studies have provided a unique view of the nature of environmental risk factors for psychiatric disorders. The twin-study method allows researchers to estimate the relative importance of 3 main sets of risk factors on psychopathology: genes, shared environment, and unshared environment. Shared environment refers to any environmental feature shared by siblings. Examples include social class and the nature of discipline from parents. Unshared environment refers to any environmental feature that siblings do not share. Examples include head injuries and exposure to different peer groups. Twin studies suggest that most environmental risk factors for psychopathology are those not shared by siblings (14,15).

For any disease, understanding the parameters of the target population helps create a strategy for preventive intervention. We take as examples the prevention of 2 diseases—pellagra and syphilis—that in the past were responsible for a large portion of mental disorders, including psychoses, worldwide. By understanding the effective prevention strategies for these known causes of mental disorders, we can compare alternative prevention strategies aimed at those processes where the etiology is not fully known. The first prevention strategy, illustrated by the prevention of pellagra-associated psychosis, involves the direct targeting of modifiable risk factors. In the southern US, pellagra was responsible for a large percentage of hospitalizations for mental disorders in the early part of the 20th century. After it was recognized that a dietary deficiency in riboflavin caused pellagra, direct targeting of this risk factor by dietary supplementation virtually eliminated this disease and its consequent psychosis in many parts of the world. This dietary strategy reaches a large segment of the population, and we can therefore refer to it as population-based.

Identifying risk factors can also lead to the development of interventions that target a specific group of individuals who share that risk factor. Untreated syphilis can lead to neurosyphilis with symptoms of grandiosity and psychotic behaviour, as well as dementia and depression. Although the disease has not been eliminated, antibiotic treatment has virtually eliminated the most serious mental conditions associated with its later stages. Two common targeted screening strategies involve screening couples before marriage and screening commercial sex workers. Appropriate treatment is then provided to those with positive serological tests. The geographic distribution of syphilis cases is also not random. Impoverished communities living with limited clinic access and in close proximity to trucking thoroughfares are at elevated risk for contracting the disease (16).

In these examples, prevention programs first screen target individuals based on a risk characteristic (for example, sex worker), but the intervention is directed at another factor that is known to be causal in the development of the disorder (syphilis infection). Another approach is to select a group based on a modifiable risk factor and then eliminate that risk factor. For example, improving the care of pregnant women with schizophrenia or pregnant women known to have partners with schizophrenia could reduce pregnancy and delivery complications and, consequently, the risk of schizophrenia in their children. As another example, some data suggest that the nature of family relationships may be a risk factor for symptoms of schizophrenia (for example, [17]). Thus, family interventions might reduce stressors that affect vulnerable family members. This could reduce the risk for schizophrenia among vulnerable adolescents.


Our Current Knowledge of Risk and Protective Factors for Schizophrenia

In this section, we briefly review our current knowledge of risk and protective factors for schizophrenia, focusing on a group of factors for which there is evidence of a causal link with the disorder. Factors associated with “schizotaxia,” the predisposition to schizophrenia, may predict subsequent schizophrenia, but these have been reviewed elsewhere (18).

Genes

The cumulative evidence from over a century of research overwhelmingly implicates genes in the etiology of schizophrenia (19–21). Twin studies consistently find higher concordance rates of schizophrenia among monozygotic (MZ) twins than among dizygotic (DZ) twins (22), and adoption studies show that familial transmission is mostly mediated by genetic, not adoptive, relationships (23,24). No single major “schizophrenia gene” has yet been discovered (25), and it is likely that no such gene exists. Mathematical analyses suggest that many genes are involved in the etiology of schizophrenia (26), and that the effect of any single gene on risk for the disorder is likely to be small (27).

Traditionally, genetic risk for schizophrenia has been estimated from the pattern of schizophrenia prevalence in relatives. A review of 40 European studies, selected for similarities in diagnostic and ascertainment procedures and performed between 1920 and 1987 (19), showed the following approximate lifetime risks for schizophrenia to relatives of schizophrenia patients: parents, 6.0%; siblings, 9.0%; offspring having 1 parent with schizophrenia, 13.0%; and offspring having 2 parents with schizophrenia, 46.0%. Note that the risk to offspring exceeds the risk to parents, which is unexpected because similar risks to first-degree biological relatives (who share on average 50% of genes) would be anticipated in a standard genetic model. The difference occurs because schizophrenia has an adverse effect on the probability of reproducing, whereas parents, by definition, have already reproduced. Thus, parents are on average a more selective and less vulnerable group than are offspring. The risks to second-degree relatives (who share on average 25% of genes) ranged from 6.0% for half-siblings to 2.0% for uncles and aunts. First cousins, a type of third-degree relative (who share on average 12.5% of genes) had an average risk of 2.0%. Using more stringent diagnostic criteria, modern family studies find a lower overall prevalence in families but have confirmed that the pattern of risk is consistent with the idea that genes underlie the familial transmission of the disorder (28,29).

The discovery of specific susceptibility genes for schizophrenia may yield more accurate and useful estimates of the risk to individuals than can be inferred from the degree of relatedness to affected family members. The isolation of such genes may also assist in identifying individuals, families, and even whole groups of families who may be at either an elevated or reduced risk for schizophrenia. Through large-scale collaborative research endeavours and metaanalysis, several gene variants have been found to confer excess risk for the disorder. For example, Williams and others identified an association between a mutation in the 5-HT2A receptor gene and schizophrenia in a large, multicentre case-control study (30) and verified this association by metaanalysis (31). A functional polymorphism of the D3 subtype of dopamine receptor has also been found to be associated with schizophrenia (32,33), but this association appears to be strongest for, if not exclusive to, samples of European descent. Another dopamine receptor subtype gene, that for the D2 subtype, contains a functional gene variant also associated with schizophrenia (34). This variant is rare in the population (prevalence 5.0%), but when present, it significantly increases risk for schizophrenia.

Interestingly, genes implicated in schizophrenia code for proteins that are integral to monoamine neurotransmission, and this fits in with our current understanding of the major neurotransmitter dysfunctions of schizophrenia. More research is needed to identify other genes associated with schizophrenia, to determine how they affect the brain, and to determine whether the genes identified combine in an additive or interactive fashion to modify the risk for schizophrenia. The findings to date demonstrate the complexity and heterogeneity of the genetic etiology of schizophrenia.

1 | 2 | 3 | 4 | 5


CJP Archives in English | Archives RCP en français
Supplements and Position Paper Inserts |
Lignes directrices cliniques, énoncés de principe et communiqués
Author Index to 2001 | Index RCP des auteurs 2001
Subject Index to 2001 | Index RCP des sujets 2001
Information for Contributors | Information à l'intention des auteurs
Style Notes for Contributors
Subscription Rates | Prix d'abonnements
Advertising Rates | Tarifs publicitaires
CPA Home | Page d'accueil